In breast cancer, CD10+ stromal cells, which likely originate from BM-MSCs, exhibit a gene signature associated with poor prognosis and non-response to chemotherapy in HER2-positive patients [270]. This evidence concerns the gene ERBB2 and breast carcinoma.